{"id":"https://openalex.org/W2395837104","doi":null,"title":"[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].","display_name":"[New oral anticancer drug, TS-1 (S-1)--from bench to clinic].","publication_year":2001,"publication_date":"2001-06-01","ids":{"openalex":"https://openalex.org/W2395837104","mag":"2395837104","pmid":"https://pubmed.ncbi.nlm.nih.gov/11432358"},"language":"ja","primary_location":{"id":"pmid:11432358","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11432358","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"English Abstract"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113793342","display_name":"Tetsuhiko Shirasaka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120269","display_name":"Taiho Pharmaceutical (Japan)","ror":"https://ror.org/02v50dx14","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210120269"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"T Shirasaka","raw_affiliation_strings":["Laboratory, Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory, Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Co., Ltd","institution_ids":["https://openalex.org/I4210120269"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112132611","display_name":"M. Tsukuda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Tsukuda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113947190","display_name":"Yukio Inuyama","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y Inuyama","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5112141513","display_name":"T Taguchi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T Taguchi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5237,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.68968518,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"28","issue":"6","first_page":"855","last_page":"64"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.5059000253677368,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.5059000253677368,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.30709999799728394,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0364999994635582,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/s-1","display_name":"S-1","score":0.8190000057220459},{"id":"https://openalex.org/keywords/tegafur-uracil","display_name":"tegafur-uracil","score":0.8859999775886536},{"id":"https://openalex.org/keywords/fluoropyrimidine","display_name":"fluoropyrimidine","score":0.7350000143051147},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.8360000252723694},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.5870000123977661},{"id":"https://openalex.org/keywords/stomatitis","display_name":"stomatitis","score":0.6489999890327454},{"id":"https://openalex.org/keywords/advanced-gastric-cancer","display_name":"advanced gastric cancer","score":0.6299999952316284},{"id":"https://openalex.org/keywords/recurrent-gastric-cancer","display_name":"recurrent gastric cancer","score":0.9480000138282776},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7620000243186951},{"id":"https://openalex.org/keywords/clinical-pharmacology","display_name":"clinical pharmacology","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C2777299880","wikidata":"https://www.wikidata.org/wiki/Q413370","display_name":"Tegafur","level":3,"score":0.7928773760795593},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6406823992729187},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.6108416318893433},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5912685990333557},{"id":"https://openalex.org/C2779051857","wikidata":"https://www.wikidata.org/wiki/Q911386","display_name":"Stomatitis","level":2,"score":0.5719038844108582},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5616766810417175},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5095461010932922},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4574645161628723},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38146302103996277},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2481519877910614}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005641","descriptor_name":"Tegafur","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006258","descriptor_name":"Head and Neck Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010094","descriptor_name":"Oxonic Acid","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013274","descriptor_name":"Stomach Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:11432358","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11432358","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"English Abstract"},{"id":"mag:2395837104","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11432358","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2153244200","https://openalex.org/W7097024065","https://openalex.org/W2419532975","https://openalex.org/W2032540605","https://openalex.org/W2396325839","https://openalex.org/W236285899","https://openalex.org/W1506696192","https://openalex.org/W3162492604","https://openalex.org/W2035456243","https://openalex.org/W2018619890"],"abstract_inverted_index":{"We":[0,26,94],"describe":[1],"in":[2,78,90,124,138,208,213,248,262,270,283,347,357,390,431,446,513,536],"this":[3,394,408,447],"paper":[4],"a":[5,12,34,63,96,103,107,133,166,234,296,328,374],"therapeutic":[6,529],"modality":[7,530],"which":[8,69,87,288],"is":[9,70,88],"based":[10],"on":[11,162],"self-rescuing":[13],"concept":[14],"(SRC)":[15],"featuring":[16],"dual":[17],"activity,":[18],"i.e.,":[19,199],"effect-enhancing":[20],"activity":[21,44,129,187],"and":[22,30,45,80,115,122,130,175,195,202,266,323,335,352,368,404,429,457,469,520,545],"adverse":[23,131,465,487,503],"reaction-reducing":[24],"activity.":[25],"present":[27],"the":[28,50,54,91,148,151,176,209,214,271,276,319,399,427,458,483,527,538,552],"theory":[29],"practice":[31],"of":[32,53,110,126,169,224,231,236,241,258,287,321,325,345,377,401,421,474,485,494,510,540],"S-1,":[33,101,120],"novel":[35,97],"oral":[36,58,98,145,293],"fluoropyrimidine":[37,59],"anticancer":[38,43,99,128,547],"agent":[39],"designed":[40],"to":[41,245,396,412,425,498,502],"enhance":[42],"reduce":[46],"gastrointestinal":[47,92,534],"toxicity":[48],"through":[49],"deliberate":[51],"combination":[52,104],"following":[55],"components:":[56],"an":[57,81],"agent,":[60,100],"tegafur":[61],"(FT);":[62],"DPD":[64],"inhibitor":[65,83],"(CDHP:":[66],"5-chloro-2,":[67],"4-dihydroxypyridine)":[68],"about":[71,156],"200-fold":[72],"more":[73,189],"potent":[74],"than":[75,193,212],"uracil":[76],"used":[77,141],"UFT;":[79],"ORTC":[82],"(Oxo:":[84],"potassium":[85],"oxonate)":[86],"localized":[89],"tract.":[93],"devised":[95],"as":[102,274],"drug":[105,402],"with":[106,191,264,295,331,349,433,439],"molar":[108],"ratio":[109],"1:0.4:1":[111],"for":[112,142,181,275,333,373,515,531,551],"FT,":[113,121],"CDHP,":[114],"Oxo,":[116],"respectively.":[117],"To":[118,525],"compare":[119],"UFT":[123],"terms":[125],"their":[127],"reactions,":[132],"colon":[134],"cancer":[135,354,519],"implantation":[136],"model":[137],"rats":[139],"was":[140,188,303,310,314,355,381,388,410,423,454,460,480,489],"4-week":[143],"consecutive":[144,292],"administration":[146,228,294,403],"from":[147],"time":[149,308],"when":[150],"postimplantation":[152],"tumor":[153,160,177],"weight":[154,203],"become":[155],"2":[157],"g.":[158],"The":[159,299,450,463,472],"disappeared":[161],"day":[163],"16":[164],"at":[165,182,233],"given":[167,315],"dose":[168,235],"S-1":[170,192,210,232,259,313,346,422,511,544],"(as":[171],"22.5":[172],"mg/kg":[173],"FT),":[174],"did":[178],"not":[179],"reappear":[180],"least":[183],"three":[184],"months.":[185],"Antitumor":[186],"marked":[190],"FT":[194],"UFT.":[196],"Adverse":[197],"reaction,":[198],"stomatitis,":[200],"depilation,":[201],"loss,":[204],"were":[205,243,260,363,444,467],"less":[206],"frequent":[207],"group":[211],"other":[215,486,546],"groups.":[216],"A":[217,339,415],"clinical":[218,256,277,343,419,448,508,541],"pharmacology":[219,278],"study":[220,344],"examined":[221],"blood":[222,405],"concentrations":[223,240],"5-FU":[225,242],"after":[226,229,327,398],"twice-a-day":[227],"meals":[230],"40":[237],"mg/m2.":[238],"Blood":[239],"60":[244],"200":[246],"ng/ml":[247],"all":[249],"twelve":[250],"patients":[251,263,348,432,438],"examined.":[252],"Late":[253,505],"phase":[254,341,417,506],"II":[255,342,418,507],"trials":[257,509,542],"conducted":[261,356,424],"advanced":[265,334],"recurrent":[267,336],"stomach":[268,337],"cancers,":[269,532,535],"same":[272],"regimen":[273],"study.":[279],"It":[280],"basically":[281],"consisted":[282],"four":[284],"cycles,":[285],"each":[286],"comprised":[289],"4-week,":[290],"twice-a-day,":[291],"2-week":[297],"withdrawal.":[298],"overall":[300,451],"response":[301,366,371,375,452],"rate":[302,376,453],"44.6%":[304],"(45/101).":[305],"Median":[306],"survival":[307],"(MST)":[309],"224":[311],"days.":[312,383,462],"manufacturing":[316],"approval":[317],"by":[318],"Ministry":[320],"Health":[322],"Welfare":[324],"Japan":[326],"priority":[329],"review,":[330],"indications":[332],"cancers.":[338],"late":[340,416],"advanced/recurrent":[350],"head":[351],"neck":[353],"59":[358],"eligible":[359],"patients.":[360],"Objective":[361],"responses":[362],"4":[364,385],"complete":[365],"(CR)":[367],"13":[369],"partial":[370],"(PR),":[372],"28.8%":[378],"(17/59).":[379],"MST":[380,459],"344":[382],"Grade":[384],"hemoglobin":[386],"decrease":[387],"observed":[389],"one":[391],"case;":[392],"however,":[393],"returned":[395],"normal":[397],"termination":[400],"transfusion.":[406],"Therefore,":[407],"event":[409],"confirmed":[411],"be":[413,499],"reversible.":[414],"trial":[420],"evaluate":[426],"efficacy":[428],"toxicities":[430],"metastatic":[434,441],"colorectal":[435,442,516],"carcinoma.":[436],"Sixty-three":[437],"measurable":[440],"carcinoma":[443],"enrolled":[445],"trial.":[449],"35.5%":[455],"(22/62),":[456],"378":[461],"main":[464],"reactions":[466,488],"myelosuppression":[468],"GI":[470],"toxicities.":[471],"incidence":[473,484],"neutropenia":[475],"(Grade":[476],"3":[477],"or":[478,491],"4)":[479],"13%,":[481],"while":[482],"10%":[490],"below.":[492],"None":[493],"53":[495],"outpatients":[496],"required":[497],"hospitalization":[500],"due":[501],"reactions.":[504],"are":[512],"progress":[514],"cancer,":[517],"breast":[518],"non-small":[521],"cell":[522],"lung":[523],"cancer.":[524],"establish":[526],"standard":[528],"including":[533],"Japan,":[537],"conduction":[539],"combining":[543],"drugs":[548],"holds":[549],"promise":[550],"future.":[553]},"counts_by_year":[{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2016-06-24T00:00:00"}